Imaging Endpoints
, a core medical imaging lab focused on accelerating the crucial clinical trial process for pharmaceutical and medical device manufacturers, has officially launched.
Pharmaceutical and medical device manufacturers understand that medical imaging plays an integral part in the clinical trial process by helping to validate which drugs and devices are demonstrating efficacy. By identifying what is referred to as “imaging endpoints” (the overall outcome the clinical trial protocol is designed to evaluate), these companies, with the support of a core imaging lab, can effectively obtain results and determine if those endpoints are met. Imaging Endpoints provides the efficacy support needed to garner FDA approval to introduce new products to the market with the intent of improving patient outcomes.
Imaging Endpoints sets out to expedite the clinical trial process and serves as a central hub for collection, processing, quality review and standardized radiologic analysis of medical images. Additionally, Imaging Endpoint radiologists serve as blind readers and provide medical image interpretation, a fundamental component of the core imaging lab business for clinical trial sponsors.
Imaging Endpoints specializes in oncologic, cardiovascular, neurological and musculoskeletal trials. Imaging Endpoints is comprised of a group of board-certified, fellowship-trained radiologists and project managers.
Imaging Endpoints’ project managers have experience in clinical trials within pharmaceutical and medical device companies, and its parent company has functioned as a clinical imaging site in numerous trials.
Ronald Korn, MD, PhD, serves as Imaging Endpoints’ medical director.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.